Sumagen Canada

Sumagen Canada is a biotechnology company dedicated to the development of a preventive vaccine for HIV/AIDS. The company's core asset, SAV001, represents a novel approach as a whole-killed genetically modified HIV-1 vaccine. This candidate successfully completed a Phase 1 clinical trial in the United States, which demonstrated no safety concerns and showed significant boosting of HIV-specific antibodies. Developed in partnership with researchers at Western University, the technology involves inactivating the virus through chemical treatment and radiation. Sumagen Canada is currently focused on advancing the vaccine into Phase 2 clinical trials to assess its efficacy in a larger human population. The company operates as a subsidiary of the South Korean firm Sumagen Co., Ltd., leveraging international expertise to address the global HIV epidemic.